American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause–2017 Update

Endocrine Practice - Tập 23 Số 7 - Trang 869-881 - 2017
Rhoda H. Cobin1, Neil F. Goodman2
1Icahn School of Medicine at Mount Sinai, New York, New York
2University of Miami Miller School of Medicine, Miami, Florida

Tóm tắt

Từ khóa


Tài liệu tham khảo

Goodman, 2011, AACE medical guidelines for clinical practice for diagnosis and treatment of menopause, Endocr Pract, 17

Wharton, 2013, Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog), Brain Res, 1514, 12, 10.1016/j.brainres.2013.04.011

NAMS 23rd Annual Meeting, Orlando, Florida, October 3–6, 2012. Available at: http://www.menopause.org/annual-meetings/2012-meeting/keeps-report. Accessed May 25, 2017.

Hodis, 2016, Vasuclar effects of early versus late postmenopausal treatment with estradiol, N Engl J Med, 374, 1221, 10.1056/NEJMoa1505241

Schierbeck, 2012, Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial, BMJ, 345, e6409, 10.1136/bmj.e6409

Rossouw, 2012, Study had insufficient power to investigate safety, BMJ, 345, e8146, 10.1136/bmj.e8146

Manson, 2013, Menopausal hormone therapy and health outcomes during the intervention and extended posts stopping phases of the Women's Health Initiative randomized trials, JAMA, 310, 1353, 10.1001/jama.2013.278040

Bassuk, 2014, Menopausal hormone therapy and cardiovascular disease risk: utility of biomarkers and clinical factors for risk stratification, Clin Chem, 60, 68, 10.1373/clinchem.2013.202556

Wild, 2013, Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials, Menopause, 20, 254, 10.1097/gme.0b013e31826f80e0

Wolff, 2013, Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estrogen prevention study (KEEPS), Fertil Steril, 99, 1385, 10.1016/j.fertnstert.2012.11.053

Huang, 2009, Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women, Menopause, 16, 639, 10.1097/gme.0b013e31819c11e4

Thurston, 2016, Menopausal hot flashes and carotid intima media thickness among midlife women, Stroke, 47, 2910, 10.1161/STROKEAHA.116.014674

Crandall, 2017, Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Womens' Health Initiative Study, Menopause, 24, 252, 10.1097/GME.0000000000000763

Połać, 2013, Coagulation and fibrinolytic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration, Gynecol Endocrinol, 29, 165, 10.3109/09513590.2012.730567

Slater, 2001, Comparison of estrogen and androgen levels after oral estrogen replacement therapy, J Reprod Med, 46, 1052

L'Hermite, 2013, HRT optimization using transdermal estradiol plus micronized progesterone, a safer HRT, Climacteric, 16, 44, 10.3109/13697137.2013.808563

Canonico, 2008, Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis, BMJ, 336, 1227, 10.1136/bmj.39555.441944.BE

Sweetland, 2012, Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study, J Thromb Haemost, 10, 2277, 10.1111/j.1538-7836.2012.04919.x

Shufelt, 2014, Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study, Menopause, 21, 260, 10.1097/GME.0b013e31829a64f9

Renoux, 2010, Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study, BMJ, 340, c2519, 10.1136/bmj.c2519

Qureshi, 2016, Hormone replacement therapy and the risk of subarachnoid hemorrhage in postmenopausal women, J Neurosurg, 124, 45, 10.3171/2014.12.JNS142329

Fournier, 2008, Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer, J Clin Oncol, 26, 1260, 10.1200/JCO.2007.13.4338

Brinton, 2014, Breast cancer risk in older women: results from the NIH-AARP diet and health study, Cancer Causes Control, 25, 843, 10.1007/s10552-014-0385-3

Bourgain, 1990, Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure, Hum Reprod, 5, 537, 10.1093/oxfordjournals.humrep.a137138

Allen, 2010, Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition, Am J Epidemiol, 172, 1394, 10.1093/aje/kwq300

Biberoglu, 2016, Luteal phase support in intrauterine insemination cycles: a prospective randomized study of 300 mg versus 600 mg intravaginal progesterone tablet, Gynecol Endocrinol, 32, 55, 10.3109/09513590.2015.1077382

Fernández-Murga, 2012, Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol, Climacteric, 15, 455, 10.3109/13697137.2011.644360

Furness, 2012, Hormone therapy in postmenopausal women and risk of endometrial hyperplasia, Cochrane Database Syst Rev, 8, CD000402

Canonico, 2010, Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study, Arterioscler Thromb Vasc Biol, 30, 340, 10.1161/ATVBAHA.109.196022

Stanczyk, 2015, Reprint of “Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?”, J Steroid Biochem Mol Biol, 153, 151, 10.1016/j.jsbmb.2015.08.013

Kerlikowske, 2003, Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population, J Clin Oncol, 21, 4314, 10.1200/JCO.2003.05.151

Collins, 2005, Breast cancer risk with postmenopausal hormonal treatment, Hum Reprod Update, 11, 545, 10.1093/humupd/dmi028

Fournier, 2005, Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, Int J Cancer, 114, 448, 10.1002/ijc.20710

Stanczyk, 2013, Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects, Endocr Rev, 34, 171, 10.1210/er.2012-1008

Shao, 2012, Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study, Neurology, 79, 1846, 10.1212/WNL.0b013e318271f823

Stuenkel, 2017, Menopause hormone therapy and diabetes, Climacteric, 20, 11, 10.1080/13697137.2016.1267723

Files, 2011, Bioidentical hormone therapy, Mayo Clin Proc, 86, 673, 10.4065/mcp.2010.0714

GalsonSK.Pharmacy Compounding/Compounding of Bio-identical Hormone Replacement Therapies. Available at: https://www.fda.gov/newsevents/testimony/ucm154031.htm. Accessed May 31, 2017.

Available at: http://www.fda.gov/forconsumers/byaudience/forwomen/ucm118624.htm.

Sharifi, 2014, Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy, Expert Rev Clin Pharmacol, 7, 281, 10.1586/17512433.2014.893819

Mirkin, 2013, Tissue-selective estrogen complexes for postmenopausal women, Maturitas, 76, 213, 10.1016/j.maturitas.2013.06.003

Rosen HN, Rosen CJ, Mulder JE.. Selective estrogen receptor modulators, Up to Date. 2017;.

Rietjens, 2017, The potential health effects of dietary phytoestrogens, Br J Pharmacol, 174, 1263, 10.1111/bph.13622

Guthrie, 2015, Pooled analysis of six pharmacologic and nonpharmacologic interventions for vasomotor symptoms, Obstet Gynecol, 126, 413, 10.1097/AOG.0000000000000927

Carroll, 2015, Critical appraisal of paroxetine for the treatment of vasomotor symptoms, Int J Womens Health, 7, 615, 10.2147/IJWH.S50804

Binkhorst, 2013, Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen, Breast Cancer Res Treat, 139, 923, 10.1007/s10549-013-2585-z

Saadati, 2013, The effect of gabapentin on intensity and duration of hot flashes in postmenopausal women: a randomized controlled trial, Glob J Health Sci, 5, 126, 10.5539/gjhs.v5n6p126

Pinkerton, 2014, Phase 3 randomized controlled study of gastro-retentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause, Menopause, 21, 567, 10.1097/GME.0b013e3182a7c073

Bordeleau, 2010, Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors, J Clin Oncol, 28, 5147, 10.1200/JCO.2010.29.9230

L'Espérance, 2013, Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations, Support Care Cancer, 21, 1461, 10.1007/s00520-013-1732-8

Overk, 2008, High-content screening and mechanism-based evaluation of estrogenic botanical extracts, Comb Chem High Throughput Screen, 11, 283, 10.2174/138620708784246022

Gaube, 2007, Gene expression profiling reveals effects of Cimicifuga racemosa (L.) NUTT. (black cohosh) on the estrogen receptor positive human breast cancer cell line MCF-7, BMC Pharmacol, 7, 11, 10.1186/1471-2210-7-11

Mercado-Feliciano, 2012, An ethanolic extract of black cohosh causes hematological changes but not estrogenic effects in female rodents, Toxicol Appl Pharmacol, 263, 138, 10.1016/j.taap.2012.05.022

Bolle, 2007, Estrogen-like effect of a Cimicifuga racemosa extract sub-fraction as assessed by in vivo, ex vivo and in vitro assays, J Steroid Biochem Mol Biol, 107, 262, 10.1016/j.jsbmb.2007.03.044

Fritz, 2014, Black cohosh and breast cancer: a systematic review, Integr Cancer Ther, 13, 12, 10.1177/1534735413477191